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Regulatory T cells are important for ensuring that the immune system does not attack self and does not over-
react to external antigens. Understanding how these cells develop and maintain stable function provides
general insights into cellular differentiation in general, as well as new opportunities for therapeutic manipu-
lation.Introduction
The immune system protects us against
infectious pathogens and has evolved to
do this while minimizing damage to self-
tissues. Self-tolerance is enabled by dele-
tion, within the primary lymphoid organs
(marrow and thymus) of lymphocytes
withself-reactive receptors. It hasbecome
clear in the past 20 years that active regu-
lation mediated by CD4+ T cells is also
necessary.
Understated experiments some 20
years ago (Hall et al., 1985; Kong et al.,
1989; Powrie and Mason, 1990; Qin et al.,
1993; Sakaguchi et al., 1982) demon-
strated that CD4+ T cells could, in
certain circumstances, prevent damaging
immune reactions. The importance of
these early studies was not properly
recognized because the putative regula-
tory cells could not be experimentally
separated from CD4+ T cells with immune
function. The first operational handle on
regulatory T (Treg) cells wasCD25, a chain
of the IL-2 receptor (Sakaguchi et al.,
1995), although it proved to be far
from perfect, given that this receptor is
expressed on activated T cells. A set
of thymus-derived ‘‘natural’’ regulators
were defined on the basis of expression
of CD25 in a resting immune system. Just
as for CD4+ andCD8+ T cell differentiation,
the assumption was that these cells
should be considered as a CD4+ lympho-
cyte subset. The finding that CD4+CD25+
T cells could suppress T cell proliferation
in vitro (Thornton and Shevach, 1998) led
to the widespread adoption of this as an
assay to measure functional Treg cells in
lymphocyte populations.
Thenextmajorbreakthrough,effectively
the ‘‘clincher’’ for any remaining disbe-
lievers, was the finding that patients with
IPEX syndrome, a disease with diverse
immunopathologies, carried mutations inthe gene for the transcription factor
FoxP3 (Chatila et al., 2000).Murine studies
clearly implicated FoxP3 as the transcrip-
tion factor needed to direct CD4+ T cells
to become Treg cells (Fontenot et al.,
2003; Hori et al., 2003; Khattri et al., 2003).
The last importantpieceof the regulatory
T cell jigsaw came with the finding that
Foxp3+ Treg cells could also be induced
outside of the thymus through signals
mediated via the T cell receptor (TCR) in
conjunction with an extrinsic source of
the cytokine TGF-b (Chen et al., 2003).
Moreover, TGF-b was found to be neces-
sary for induction of peripheral tolerance
and induction of FoxP3+ Treg cells in vivo
(Cobbold et al., 2004; Daley et al., 2007).
The subsequent demonstration that TGF-b
was also needed to convert naive T cells
to other functional phenotypes (Th17 and
Th9 cells) (Bettelli et al., 2006; Veldhoen
et al., 2006; Veldhoen et al., 2008) opened
up a much-needed discussion on what
factors determined functional polarization
of T cells, how stable that differentiated
state was, and the extent to which any
T cell could exhibit the plasticity to change
function. Obviously, the issue of plasticity
is a critical one for those wishing to apply
in vitro-expanded Treg cells as a personal-
ized form of treatment for autoimmune
diseases.
Challenging Questions in the Field
In this issue of Immunity, the series of
review articles on FoxP3+ Treg cells are
timely and offer an appraisal of the main
issues introduced above. They address
the following questions: What are the
differences between natural Treg cells
and induced ones? How do these Treg
cells develop? What factors determine
the stability or plasticity of Treg cells? At
what stages of an immune response can
Treg cells act, and where might they doImmunitthis? Are there specialized microenviron-
ments that favor and reinforce their gener-
ation and maintenance? How do Treg
cells regulate immune function? Can we
harness them as therapeutic agents in
their own right?
JosefowiczandRudensky (2009) assess
the relative contributions of natural,
thymic-derived Treg (nTreg) cells and
periphery-induced Treg (iTreg) cells to
the functional regulatory cell repertoire
and argue for somewhat different signal-
ing needs mediated through the TCR
that favor development of each. Their
analysis of the influential transcription
factors, and other inductive conditions
for iTreg cells, draws attention to the
need for a supportive microenvironment
(e.g., gut-associated lymphoid tissue) for
their generation. They also analyze care-
fully those factors that can determine
stability of Treg cell phenotype and Foxp3
expression in vivo, with prospects for
pharmacological enhancement of those
epigenetic mechanisms to ensure optimal
function.
Zhou et al. (2009) focus specifically on
the issue of plasticity and the extent to
whichTregcells andTh17cells canchange
their functional commitment as a result of
particular cytokine milieus or through
competing transcription factors and other
antagonistic mediators. Their analysis of
epigeneticmechanisms for fixingcell func-
tion indicate that within seemingly polar-
ized cell populations, there still remain
cells poised to ‘‘turn’’ if the right conditions
are met.
Curotto de Lafaille and Lafaille (2009)
examine the division of labor between
nTregand iTregcells. Theyhighlight exam-
ples in which optimal outcomes require
both and describe situations in which
one suffices. iTreg cells, for example, can
sometimes be sufficient to establishy 30, May 22, 2009 ª2009 Elsevier Inc. 613
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Treg cells migrate to sites within the grafted tissue. Activated Treg cells can convert ATP released by inflamed tissues to adenosine via the ectoenzymes CD39
and CD73 (Deaglio et al., 2007). Local adenosine contributes to the initial immunosuppressive milieu. Treg cells also inhibit the maturation and migration of
dendritic cells (DCs), and these ‘‘semi-mature’’ (sm) DCs express Indoleamine 2,3-dioxygenase (IDO) and arginase, which locally deplete tryptophan and argi-
nine, and further amplify the tolerogenic microenvironment (Mellor et al., 2004). The induction of hemoxygenase (HO) by the induction of tissue-protective
responses also generates locally immunosuppressive carbon monoxide (CO) (Soares et al., 2001) Each of these components within the microenvironment,
some in synergy with TGF-b, further reinforce the local anti-inflammatory state such that any naive T cell that migrates into this area is converted, via infectious
tolerance, to an induced (iTreg) cell. The iTreg cell then acts to expand and yet further amplify the tolerogenic milieu.tolerance in their own right and can reduce
inflammation and allow remodeling of
tissues. They can also be an impediment
to vaccination and cancer therapy. Possi-
ble explanations for differential function
between the two types are discussed and
the issue of context of antigen exposure
(tissue microenvironments) is raised as
a missing factor in understanding how
these cells function.
Shevach (2009) discusses how Treg
cells exert their suppressive function.
Although an initial proponent of direct
T-T suppression at the inductive stage,
Shevach now considers decommission-
ing of antigen-presenting cells as a real-
istic alternative and offers a cautious
assessment of in vitro systems that not
adequately reflect the function of Treg
cells in vivo.
Finally, Riley et al. (2009) assess the
merits and risks of using adoptive transfer
of expanded regulatory T cells for the
treatment of autoimmune diseases and in
hemopoietic transplantation. Even if Treg
cells have failed toprevent anautoimmune
disease, the processes involved in their
selective in vitro expansion may correct
any deficit. Progress in defining good
manufacturing practice (GMP) conditions614 Immunity 30, May 22, 2009 ª2009 Elsevfor such therapies and in minimizing
possible risks is outlined.
A clear message emerging from all
these articles is that Treg cells play an
important role in the immune system and
have the ability to exert very powerful
control of innate and adaptive immune
functions. That potency is no better
exemplified than in the arena of transplan-
tation tolerance.
How Do Treg Cells Operate
in Transplantation Tolerance?
The capacity of Treg cells to prevent graft
rejection has not only demonstrated the
enormous potency of Treg cells but has
also provided convenient experimental
readouts to test mechanism and to mani-
pulate Treg cells for therapeutic purposes.
Short pulses of therapeutic nonablative
antibodies directed to the T cell corecep-
tors CD4 and CD8 can produce long-
term acceptance (Cobbold et al., 2004;
Qin et al., 1993) and tolerance of geneti-
cally mismatched grafts. Tolerance is de-
pendent on the activities of both natural
and induced Treg cells and is dependent
on TGF-b signaling to T cells (Cobbold
et al., 2004; Daley et al., 2007). These
Treg cells are potent enough to mediateier Inc.‘‘linked suppression’’ toward third-party
antigens, in the same tissue as the toler-
ated set. ‘‘Linked suppression’’ implied
that Treg cells mediated suppression
within the context of the antigen-bearing
tissues and led to the discovery of Treg
cells in tolerated tissues (Graca et al.,
2002). The impact of the cohort of Treg
cells brought into action by therapy goes
well beyond those cells, given that new
cohorts of Treg cells are continuously
recruited over time (Qin et al., 1993). This
process that we have coined ‘‘infectious
tolerance’’ has not yet been fully explained
mechanistically. Lafaille draws attention
to the fact that there are clear examples
in which the infectiousness of tolerance
is limited (Curotto de Lafaille and Lafaille,
2009) and speculates that this may relate
to thecontext (microenvironment)wherein
antigen is presented.
The lymphoid tissuesof tolerant animals
continue to harbor alloreactive cells that
can proliferate and generate inflammatory
cytokines in response to antigen in vitro.
This, and the finding of linked suppres-
sion, suggests that the lymphoid tissue
may not be the major site of regulation
and that the tissue context or ‘‘microen-
vironment’’ may be critical. A tissue
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a reinforcing role to stabilize T cells,
demonstrating a tendency for regulation,
as long as the Treg cells can spend quality
time there. Much of the discussion in the
accompanying reviews has focused on
thegut as a very permissive and stabilizing
environment for Treg cells. There is no
reason to assume that other tissues under
attack could not provide a similar reinforc-
ing milieu.
Shevach (2009) gives ample discussion
to ‘‘in vitro’’ readouts of Treg cell-suppres-
sive function. Is it conceivable that these
have been red herrings that have some-
what misled us? The prospect that Treg
cells might act to decommission antigen-
presenting cells is getting increasing
credence and is compatible with ‘‘linked
suppression.’’ However, fixation on T cells
or dendritic cells (DCs) as the key final
targets assumes that Treg cells only oper-
ate at the inductive stage of an immune
response. Transplant models teach us
that this need not be the case (Lin et al.,
2002). Perhaps we should not look
for Treg cell molecules with direct sup-
pressive activity, but rather molecules
that initiate amplification-cascade mech-
anisms in synergy with tissue contribu-
tions (e.g., TGF-b) (Figure 1). These might
only manifest in a tissue microenviron-
ment and could be missed in vitro. If we
know how tissue and Treg cells co-oper-
ated to limit immune damage, then we
might be better able to harness those
tissue reactions for therapeutic purposes.
Curotto de Lafaille and Lafaille (2009)
discuss infectious tolerance and specu-
late that issues of context or ‘‘microenvi-
ronment’’ may explain why some model
systems see it and others do not. Shevach
offers a role for TGF-b in the process
(Andersson et al., 2008), whereas we
(unpublished data) favor the notion that
Treg cells create, within tissues through
various amplification cascades, microen-
vironments permissive for further iTreg
cell conversion (Figure 1).
The therapeutic application of Treg cells
(Riley et al., 2009) should not be underes-
timated. Even if we ignore commercialissues related to personalized cell thera-
peutics, there are genuine practical
concerns. For example, what would be
the quality-control criteria for cells that
can be reinfused into the patient? What
level of contamination with other T cells
is acceptable? What of the plasticity
issues (Josefowicz and Rudensky, 2009;
Zhou et al., 2009) with cells ‘‘poised’’ to
change function if they find themselves
in the wrong context? Perhaps more
conventional approaches to physician-
guided expansion of Treg cell in vivo pre-
dicated on conventional drugs (Tao et al.,
2007) and proteins will be possible and
preferred. After all, antibodies to T cell
receptors, coreceptors, and costimula-
torymolecules are all capable of recruiting
and favoring regulatory mechanisms
in vivo. Notwithstanding this, Riley et al.
(2009) correctly identify the control of
graft-versus-host disease (GVHD) as an
area of unmetmedical need inwhich regu-
latory cell therapy would be valuable.
Perhaps GVHD control provides the
appropriate testing ground to assess the
risks andbenefits of this formof treatment.
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